01
Cash & equivalents increased 62.5%
Cash & equivalents changed +62.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
$19.9M→$32.3MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTLeonaBio, Inc.'s latest supported as-filed period reports net income of -$19.0M, 172.9% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +62.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed -172.9% from the comparable as-filed period.
Operating income changed -166.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
LONA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-352243SEC ↗8-KAug 14, 2026Period Aug 14, 20260001193125-26-352208SEC ↗4Jul 10, 2026Period Apr 9, 20260001193125-26-300876SEC ↗4Jul 9, 2026Period Jun 23, 20260001193125-26-299927SEC ↗4Jun 24, 2026Period Jun 23, 20260001843393-26-000006SEC ↗4Jun 24, 2026Period Jun 23, 20260001580111-26-000010SEC ↗4Jun 24, 2026Period Jun 23, 20260001790314-26-000004SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Apr 9, 2026Filed Jul 10, 2026 | PERCEPTIVE ADVISORS LLCDirector | Grant Or AwardIndirect | 28,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +247.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +99.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001679039-26-000003